AngioDynamics (ANGO) vs AtriCure (ATRC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
AtriCure (ATRC) has outperformed AngioDynamics (ANGO) over the past year, gaining 56.2% versus a gain of 28.4%. Over five years, ATRC leads with a -25.3% price change compared with -48.2% for ANGO. AtriCure is the larger company by market cap ($2.71 billion vs $596.8 million), about 4.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANGO | ATRC |
|---|---|---|
| Share price | $14.19 | $53.31 |
| Market cap | $596.75M | $2.71B |
| 1-day change | -1.60% | -0.69% |
| YTD return | +10.51% | +34.76% |
| 1-year return | +28.42% | +56.24% |
| 5-year return | -48.15% | -25.30% |
| P/E ratio (TTM) | — | 253.86 |
| Forward P/E | — | 122.84 |
| EPS (TTM) | $-0.88 | $0.21 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $534.53M |
| Revenue growth (YoY) | — | +14.88% |
| Net income (latest FY) | — | $-11.45M |
| Gross margin | — | 74.98% |
| Operating margin | — | -1.77% |
| Net margin | — | -2.14% |
| 52-week high | $16.29 | $61.70 |
| 52-week low | $9.39 | $25.36 |
| Distance from 52-week high | -12.89% | -13.60% |
| Analyst consensus | none | buy |
| Avg. price target upside | +40.94% | +2.96% |
| Average volume | 506.32K | 1.10M |
| Shares outstanding | 42.05M | 50.87M |
| Employees | 632 | 1,350 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Instruments & Supplies | Medical Instruments & Supplies |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AtriCure is about 4.5 times larger than AngioDynamics by market value ($2.71B vs $596.75M).
- ATRC has outperformed ANGO by 27.8 percentage points over the past year.
About AngioDynamics
ANGO stock →AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments.
Healthcare · Medical Instruments & Supplies · 632 employees
About AtriCure
ATRC stock →AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
Healthcare · Medical Instruments & Supplies · 1,350 employees
ANGO vs ATRC FAQ
Which is bigger, AngioDynamics or AtriCure?
AtriCure (ATRC) is larger, with a market capitalization of $2.71B compared with $596.75M for AngioDynamics (ANGO).
Which stock has performed better over the past year, ANGO or ATRC?
ATRC returned +56.24% over the past 12 months, compared with +28.42% for ANGO (price return, excluding dividends). Past performance does not predict future results.
Are AngioDynamics and AtriCure in the same industry?
Yes. Both are classified in the Medical Instruments & Supplies industry within the Healthcare sector.